1BT Stock Chart & Stats
€1.09
-€0.18(-4.57%)
At close: 4:00 PM EDT
€1.09
-€0.18(-4.57%)
Day’s Range― - ―
52-Week Range€2.48 - €244.80
Previous CloseN/A
Volume0.00
Average Volume (3M)288.00
Market Cap
€3.72M
Enterprise Value€28.67M
Total Cash (Recent Filing)€5.52M
Total Debt (Recent Filing)€17.25M
Price to Earnings (P/E)<0.1
Beta0.73
Next Earnings
Apr 23, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9239.68
Shares Outstanding24,511,906
10 Day Avg. Volume100
30 Day Avg. Volume288
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.02
Price to Sales (P/S)0.00
P/FCF Ratio-3.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€71.91Price Target Upside6497.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-16.54
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Pipeline ProgressReaching 70% enrollment in a controlled Phase 2b study provides a meaningful development milestone for Allocetra and moves the program closer to efficacy validation. The FDA’s RMAT designation and defined data timeline could support regulatory momentum if results confirm earlier clinical findings.
Low Financial LeverageVery low leverage reduces the balance-sheet burden associated with financing an R&D-stage biotech and preserves flexibility for capital allocation. Expanded equity and limited debt exposure improve solvency resilience, although future value still depends on clinical execution and cash usage.
Cost Discipline And Program FocusConcentrating resources on the lead Phase 2b program and reducing workforce and management costs may lower the company’s cash burn over the next several quarters. A narrower operating focus can also improve execution discipline by directing limited capital toward the most advanced value-creating clinical milestone.
Bears Say
No Commercial RevenuePersistent zero revenue confirms that Enlivex remains dependent on research progress rather than an operating commercial franchise. Without product sales, the company has limited internally generated funding and must rely on capital resources, making clinical delays or unsuccessful trials more consequential.
Ongoing Cash Burn And Weak Earnings QualityContinued negative operating and free cash flow means the business is not self-funding and must consume capital to maintain operations. The mismatch between reported net income and cash generation further reduces confidence in recurring profitability, leaving financial performance dependent on non-operating or non-cash items.
Nasdaq Listing RiskThe delisting notification creates a material corporate and financing risk beyond ordinary biotech development uncertainty. Although Enlivex has appealed and implemented a reverse split, an adverse outcome could reduce market access, impair investor participation, and complicate future equity or debt financing.
Enlivex News
1BT FAQ
What was Enlivex Therapeutics Ltd’s price range in the past 12 months?
Enlivex Therapeutics Ltd lowest stock price was €2.48 and its highest was €244.80 in the past 12 months.
What is Enlivex Therapeutics Ltd’s market cap?
Enlivex Therapeutics Ltd’s market cap is €3.72M.
When is Enlivex Therapeutics Ltd’s upcoming earnings report date?
Enlivex Therapeutics Ltd’s upcoming earnings report date is Apr 23, 2027 which is in 176 days.
How were Enlivex Therapeutics Ltd’s earnings last quarter?
Enlivex Therapeutics Ltd released its earnings results on May 22, 2026. The company reported -€0.018 earnings per share for the quarter.
Is Enlivex Therapeutics Ltd overvalued?
According to Wall Street analysts Enlivex Therapeutics Ltd’s price is currently Undervalued.
Does Enlivex Therapeutics Ltd pay dividends?
Enlivex Therapeutics Ltd does not currently pay dividends.
What is Enlivex Therapeutics Ltd’s EPS estimate?
Enlivex Therapeutics Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enlivex Therapeutics Ltd have?
Enlivex Therapeutics Ltd has 24,511,906 shares outstanding.
What happened to Enlivex Therapeutics Ltd’s price movement after its last earnings report?
Enlivex Therapeutics Ltd reported an EPS of -€0.018 in its last earnings report. Following the earnings report the stock price went up 2.521%.
Which hedge fund is a major shareholder of Enlivex Therapeutics Ltd?
Currently, no hedge funds are holding shares in DE:1BT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Enlivex Therapeutics Ltd
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
1BT Stock 12 Month Forecast
Average Price Target
€71.91
▲(6497.58% Upside)